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Hypertrophic Cardiomyopathy -  
The Case for Alcohol Ablation Therapy
Dimitrios Tsilakis, MD, Ioannis Haveles, MD, Antonis S. Manolis, MD
A B S T R A C T
Hypertrophic cardiomyopathy (HCM). Non-surgical reduction of septal hypertrophy 
by means of transcoronary alcohol septal ablation has recently emerged as an alter-
native to surgical myectomy treatment modality in patients with HCM refractory to 
medical therapy.
I N T R O D U C T I O N
Hypertrophic cardiomyopathy (HCM) is a genetic disease caused by a variety of 
mutations in proteins, mostly but not exclusively, of the cardiac sarcomere. It is char-
acterized by hypertrophy of the left ventricle (LV), often with obstruction of the LV 
outflow tract (LVOT), in the absence of another cause, such as hypertension or aortic 
stenosis, capable of producing the degree of hypertrophy observed. It presents with 
markedly variable morphologic and hemodynamic abnormalities and clinical manifesta-
tions. The present review will briefly summarize the genetics, pathophysiology, clinical 
features and management of this disease and will mainly deal with the non-surgical 
reduction of septal hypertrophy by means of transcoronary alcohol septal ablation.
G e N e T I C  S U B S T R A T e
Hypertrophic cardiomyopathy is inherited as an autosomal dominant trait and it 
constitutes the most common genetic cardiovascular disease, affecting about 0.2% of the 
general population.1 Eleven mutations involving sarcomeric genes have been identified 
so far, the most common being beta myosin heavy chain and myosin-binding protein 
C. Moreover, there are several different mutations in each gene, the total number 
exceeding 400.2 Additionally, two non-sarcomeric protein mutations affecting cardiac 
metabolism, have been identified with a phenotype similar to HCM.3 The progress 
in molecular genetics has permitted the detection of mutated genes, thus providing 
a genetic diagnosis even in asymptomatic relatives of patients with HCM, allowing 
better counseling as well as recognition of a greater number of affected individuals.
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P A T H O l O G y ,  P A T H O P H y S I O l O G y  
A N D  C l I N I C A l  M A N I f e S T A T I O N S
The mutations in contractile protein genes appear to be di-
rectly affecting sarcomere function, leading to the characteriza-
tion of HCM as a “disease of the sarcomere”. The hypertrophy 
of the LV is a consequence of sarcomeric dysfunction. Myocyte 
disarray with loss of parallel arrangement, abnormal intercel-
lular connections and variation between individual myocytes 
constitute the major histopathologic findings. The macroscopic 
result is a usually asymmetric LV hypertrophy, involving the 
septum more than the free walls. There is a substantial diversity 
regarding the distribution and magnitude of LV hypertrophy 
even between close relatives. The right ventricle is involved 
in 30% of cases. Frequently, an abnormal mitral valve with 
elongation of leaflets or anomalous insertion of the papillary 
muscles may also be present.4
In patients with HCM, the left ventricle exhibits a hyper-
dynamic systolic function maintaining a small cavity. Left 
ventricular outflow tract obstruction occurs in 30-50%, caus-
ing a gradient between the LVOT and the aorta, sometimes 
at rest and sometimes only with drugs or maneuvers. The 
main mechanism involves a systolic anterior motion (SAM) 
of the mitral leaflets due to a suctioning effect that pulls them 
towards the hypertrophied septum (i.e. a Venturi effect).1 The 
resulting mitral regurgitation is usually mild to moderate and 
eccentric. On the contrary, when primary mitral valve disease 
exists, the direction of the regurgitant jet is usually central and 
of varying magnitude.
Diastolic function is also affected in 80% of patients, with a 
prolonged rapid filling phase and an increased atrial contribu-
tion, showing impaired LV relaxation. It constitutes a major 
cause of symptoms of dyspnea and exercise limitation both in 
obstructive and non-obstructive HCM.2
Many patients with HCM are asymptomatic and are often 
diagnosed during family screening. When symptoms do de-
velop, they are usually one or more of the following: dyspnea on 
exertion and occasionally orthopnea or paroxysmal nocturnal 
dyspnea, chest pain, presyncope and syncope, palpitations and 
fatigue.5 The degree of obstruction is not predictably correlated 
with symptoms. Some patients with severe LVOT obstruction 
remain asymptomatic for many years, while cardiac arrest or 
sudden death may be the initial presentation of the disease, 
thus underscoring the importance of family screening. Syncope 
may be due to conduction diseases, paroxysmal arrhythmias or 
abnormal vascular responses such as inappropriate vasodilata-
tion in non-exercising muscles and reflex dilatation of venous 
beds triggered by LV baroreceptors.1 Myocardial ischemia 
may be due to increased oxygen demand due to hypertrophy, 
thickening and narrowing of small intramural vessels and 
systolic compression of larger perforator and epicardial ves-
sels. The most common arrhythmia in patients with HCM is 
paroxysmal or chronic atrial fibrillation (AF), both symptom-
compromising and increasing the risk of embolic events.6 
Other arrhythmias include ventricular ectopic beats and non-
sustained ventricular tachycardia (VT) in ambulatory ECG.
N A T U R A l  H I S T O R y  A N D  P R O G N O S I S
The clinical course of HCM is quite variable and it may run 
asymptomatic for the majority of patients over long periods 
of time. The annual mortality rate is roughly 1% per year and 
is somewhat higher in children.1,4 Those patients who have 
symptoms upon presentation have a greater annual rate of car-
diac death (0.9 versus 1.9 percent, p<0.05) and sudden death 
(1.4 versus 0.1 percent, p<0.05), compared to asymptomatic 
patients.7 A small proportion of patients with HCM eventually 
progress to a stage, with reduced LV systolic function with 
dilation and wall thinning, resembling the morphologic and 
functional features of dilated cardiomyopathy, called “end-
stage” or “burned out” HCM.8
M A N A G e M e N T
A .  P R e v e N T I O N  O f  S U D D e N  C A R D I A C  D e A T H
Patients with HCM are prone to both atrial and ven-
tricular arrhythmias, the incidence of which increases with 
age. However, the majority of these are not life-threatening. 
Ventricular tachycardia and fibrillation can cause sudden 
cardiac death (SCD), most commonly during adolescence 
and young adulthood. It should be noted that many of these 
patients were totally asymptomatic and sudden cardiac death 
was the first manifestation of the disease. Moreover, HCM 
is the most common cause of death among young athletes.9 
The major risk factors for SCD are a prior cardiac arrest or 
sustained VT, a family history of HCM-related death, syncope 
especially during exertion, a hypotensive response to exercise, 
multiple episodes of non-sustained VT in ambulatory Holter 
monitoring, massive LV hypertrophy (>30 mm), presence of 
an LV apical aneurysm and the end-stage disease with LV 
systolic dysfunction.10 Certain mutations, such as beta myosin 
heavy chain and troponin T, are also associated with premature 
death more than others.11
The implantation of a cardioverter-defibrillator (ICD) is 
the preferred therapy for HCM patients at high-risk of SCD, 
both for secondary (i.e. implantation after cardiac arrest) 
and primary prevention, in patients with one or more high-
risk factors.12 The role of antiarrhythmic drugs is limited to 
patients with an ICD who experience frequent episodes, or 
as an alternative to an ICD, in high-risk patients who are not 
candidates for or choose not to have an ICD.
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B .  M e D I C A l  T R e A T M e N T
For heart failure symptoms due to diastolic dysfunction or 
LVOT obstruction, beta-blockers have been extensively used 
with excellent results both in obstructive and non-obstructive 
HCM, since they block catecholamines, thereby reducing 
LVOT gradient and improving diastolic filling time and re-
laxation. Verapamil may also provide symptomatic benefit for 
similar reasons but a number of patients with elevated venous 
pulmonary pressures may experience pulmonary edema and 
SCD.2 Disopyramide has also been proven effective, especially 
in combination with beta-blockers owing to its negative ino-
tropic effects and no evidence of proarrhythmia in these pa-
tients.13 When atrial fibrillation complicates the clinical course 
of HCM it requires aggressive intervention with anticoagula-
tion, attempts to restore sinus rhythm, both pharmacological 
and electrical, and consideration of catheter ablation of the 
pulmonary veins and the surgical maze procedure.2
N O N - M e D I C A l  T R e A T M e N T
Pharmacologic therapy is the first-line treatment for 
symptomatic patients with LVOT obstruction. For those pa-
tients that prove to be refractory to medical therapy, surgical 
myectomy, dual-chamber pacing and, more recently, ethanol 
ablation of the hypertrophied septum, have all been tried with 
variable results. It has been estimated that these approaches 
are required in approximately 5% of all patients with HCM 
and up to 30% in tertiary referral centers.1,14
1 .  D U A l  C H A M B e R  PA C I N G
Dual chamber pacing has been used in the past as an 
alternative to surgery, but studies have not shown objective 
evidence of gradient reduction and improved exercise capac-
ity.1,4 It is now primarily performed in patients undergoing ICD 
implantation, as well as selected older patients (more than 65 
years of age), or those with other indications for pacing. The 
rationale behind dual-chamber pacing is that, by initiating 
the signal in the right ventricular apex, it alters the sequential 
contraction of the basal septum, thus reducing the gradient.
2 .  S U R G I C A l  M y e C T O M y
Surgery for HCM has been a well established therapeutic 
option for over 40 years. The Morrow procedure involves 
the resection of a small portion of the basal interventricular 
septum (2 to 11 g) and has shown excellent results in reduc-
ing LVOT gradient, improving symptoms and reducing mitral 
regurgitation, but also in reducing mortality risk in severely 
symptomatic patients with obstructive HCM.15 Although ear-
lier reports mentioned a mortality rate of 4%-6%,16,17 more 
recent studies report mortality rates of less than 2%.15,18 The 
surgical results are much improved due to better anesthesia, 
myocardial protection during cardio-pulmonary bypass, and 
the use of intra-operative transesophageal echocardiography.19 
The latter permits a thorough evaluation of the surgical result 
upon the interventricular septum and, if required, the mitral 
valve, before the patient leaves the operating room.
Complications of surgical myectomy include ventricular 
septal defect due to excessive removal of cardiac muscle, aortic 
regurgitation due to the transaortic approach and left bundle 
branch block (LBBB) or complete heart block requiring a 
permanent pacemaker.20-22
3 .  A l C O H O l  S e P T A l  A B l A T I O N
Non-surgical reduction therapy or alcohol septal ablation, 
or transcoronary ablation for septal hypertrophy, or percutane-
ous transluminal septal myocardial ablation are all equivalent 
terms, referring to the creation of an iatrogenic septal infarct 
via alcohol injection in a perforating septal branch of the left 
anterior descending artery. Since it was first introduced in 
1995,23 it has been used as a therapeutic option alternative to 
surgery. The initial concept was conceived after recognizing 
that spontaneous anterior myocardial infarctions in HCM 
patients resulted in reducing the LVOT gradient. Nowadays 
more than 3500 patients have undergone the procedure.24
The appropriate selection criteria for patients’ suitability 
for alcohol septal ablation are described in the ACC/ESC 
Expert Consensus Document on hypertrophic cardiomyopathy 
(see Table 1). It is important to note that for asymptomatic or 
slightly symptomatic patients, given their relatively low risk of 
sudden cardiac death if they do not possess any high-risk fac-
tors, probably aggressive intervention is not justified although 
there are not enough data to address the question.25 Another 
important issue is the approach to patients with obstruction 
and one or more high risk factors. For this subgroup of patients 
it would be reasonable to implant an ICD and reevaluate the 
effect of sequential atrioventricular (AV) pacing on LVOT 
gradient and then, if still symptomatic, consider alcohol septal 
TABle 1. Indications for Alcohol Septal Ablation in Ob-
structive HCM.
Symptoms, functional NYHA class III to IV
Severe side effects of medical treatment
LVOT pressure gradient (maximum gradient) >30 (50) mmHg
Provokable LVOT pressure gradient (maximum gradient) >50 
(100) mmHg
Systolic anterior motion related obstruction
Mid-cavitary obstruction
Septal thickness >15 (18) mm
Suitable septal branch
HCM= hypertrophic cardiomyopathy; LVOT= left ventricular outflow 
tract; NYHA= New York heart Association
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ablation or surgery. 1
The main parts of the procedure are as follows: after the 
insertion of a temporary pacemaker in the right ventricular 
apex, for the possibility of complete heart block, a left heart 
catheterization is performed, starting with a multipurpose 
catheter to measure the LV gradient by a pull-back method.26 
This is followed by coronary angiography to identify the septal 
perforator branches of the left anterior descending coronary 
artery. An over-the-wire balloon catheter is introduced and 
inflated into those branches and contrast medium is injected 
into the balloon catheter lumen. Contrast echocardiography 
is then performed in order to identify the area supplied by 
the specific branch and thus select the most suitable for 
infarction. The use of echocardiography also ensures that 
the contrast goes only to the septum, close to the point of 
its contact with the mitral valve, and not elsewhere such as 
the papillary muscles, the LV free wall or the right ventricle. 
A small amount of absolute ethanol (usually 1-3 ml) is then 
injected very slowly and the inflation is maintained for a few 
minutes. Subsequently, a new angiography is done to ensure 
patency of the left anterior descending artery and the occlu-
sion of the target branch. Finally, the intraventricular gradient 
is remeasured to assess the acute effect of the procedure. It 
should be noted that the LVOT gradient in the acute phase 
is reduced, probably due to a stunning effect, and in the next 
few days gradually increases, possibly due to edema, until it 
finally falls over a period of weeks, due to scar formation. 24 
This has been called a ‘triphasic’ response.
The main complications arising from alcohol septal abla-
tion are summarized in Table 2.27 The in-hospital death may 
range from 1% to 4% but in specialized centers may be as 
low as 1%.27-29 The incidence of complete heart block (CHB) 
requiring a permanent pacemaker insertion was very high in 
the initial reports but it is now estimated between 14%-25%.30-35 
The introduction of myocardial contrast echocardiography, 
lower ethanol doses and ethanol infusion instead of bolus 
injection have all contributed to better results. A report from 
Mayo clinic,22 found that from 58 patients undergoing ethanol 
septal ablation 12% developed CHB and 36% developed right 
bundle brunch block (RBBB). The figures among 117 patients 
undergoing surgical myectomy were 3% for CHB and 40% 
for left bundle brunch block (LBBB). It appears that alcohol 
septal ablation produces a transmural infarction of the basal 
mid septum and adjacent right bundle branch (RBB), whereas 
surgery affects the basal anterior septum and adjacent left 
bundle branch (LBB).22 These observations are of particular 
importance in selecting patients for invasive treatment, as for 
example, a preexisting LBBB in a patient undergoing alcohol 
septal ablation is a high-risk factor for the development of 
CHB. Nevertheless, the benefit from septal ablation does not 
appear to be less in patients who develop CHB compared to 
those who do not. 33
The potential risk of ventricular septal rupture has been 
reported just once36 and was successfully treated with an 
Amplatzer ventricular septal defect closure device. Other 
dangerous complications include dissection of the left ante-
rior descending coronary artery, peri-procedural ventricular 
arrhythmias including ventricular fibrillation and pericardial 
effusion, but they are not often reported and can be dealt 
with successfully.
The concern about the possibility of long-term ventricular 
arrhythmias due to myocardial scaring has also been raised.37 
The in-hospital malignant arrhythmias can be probably attrib-
uted to ischemia, but there have been reports of ventricular 
tachycardias during follow-up.38,39 Nevertheless, the reduc-
tion of LVOT gradient and the subsequent regression in LV 
hypertrophy, due to alcohol septal ablation may also exert an 
antiarrhythmic effect.26 A study of ventricular arrhythmias 
in patients already having an ICD did not show increased 
episodes.40
The beneficial effects of alcohol septal ablation have been 
well documented over the last decade. It appears that septal 
ablation reduces LVOT gradient, increases exercise capacity 
and peak oxygen consumption and reduces NYHA class.41,42 
There is also a favorable effect on LV regional asynchrony, 
which accounts for the acute improvement in LV relaxation, 
as shown by tissue Doppler imaging.43 The long-term benefits 
derive from the localized septal infarction and the subse-
quent scar formation, which results in an increase in LVOT 
diameter and a decrease in LV mass and the extent of hyper-
trophy. Such a therapeutic remodeling of the left ventricle 
results in the observed clinical benefits.44,45 A reduction in 
nonseptal mass over time after ethanol septal ablation has 
been observed that may indicate that a degree of myocardial 
hypertrophy in HCM is in part afterload-dependent, due to 
the excessive septal hypertrophy, and is not entirely due to the 
genetic defect.44,45 There is also a beneficial effect on mitral 
regurgitation.30,42 Several studies have documented the ben-
eficial effects of alcohol septal ablation on the left ventricular 
diastolic properties.46,47 A shortening of isovolumic relaxation 
time and transmitral early diastolic deceleration time along 
with an increase in transmitral flow propagation velocity have 
been attributed to an improved relaxation profile of the left 
ventricle.47 A great part of the observed benefit is due to the 
continuous regression of LV hypertrophy as shown by Mazur 
et al.44 Finally, an improvement in the Tei Doppler index was 
shown in mid-term follow-up of patients who had undergone 
alcohol septal ablation. 48
Nevertheless, weaknesses of the procedure began to 
emerge shortly after its introduction in clinical practice. 
Younger patients with greater thickness in the interventricular 
septum were found to have a lesser degree of LVOT gradient 
reduction after septal ablation.49 Similar unsatisfactory results 
were reported by Faber et al.50 Moreover, in a substantial 
number of cases, a suitable branch for alcohol infusion may not 
be found.51,52 This would obviate the need for patient referral 
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for surgical treatment.
With regards to the comparison of alcohol ablation therapy 
with surgical myectomy, it should be noted that there are no 
randomized controlled trials. Such a trial would enlighten 
the medical community regarding the appropriate selection 
of patients for each method. The practical problems that 
arise make such a possibility quite distant.53 The different 
morphologic effects of the two procedures were shown in a 
recent prospective study of 48 patients using cardiac magnetic 
resonance (CMR). While myectomy resulted in a discrete area 
of resected tissue in the anterior septum, alcohol ablation 
caused tissue necrosis more inferiorly and extending into the 
right septal side at the midventricular level, thereby producing 
a more variable effect.54
With respect to the clinical outcomes both methods have 
proven efficacy. In a report from the Cleveland clinic, the 
authors concluded that both interventricular septal thickness 
and LVOT gradient were reduced and NYHA class was signifi-
cantly improved in patients with obstructive HCM.30 Another 
study showed similar hemodynamic and functional improve-
ments at one year in patients with a resting LVOT gradient 
at least 40 mmHg, who were severely limited by dyspnea or 
angina or had recurrent limiting presyncope or syncope.31 A 
more recent study comparing outcomes after ablation or myec-
tomy showed significantly lower post-intervention LV outflow 
gradients at rest and with provocation in the myectomy group 
accompanied by reduced systolic anterior motion of the mitral 
valve and improved NYHA class.55
C O N C l U S I O N
Both surgical myectomy and alcohol septal ablation are 
effective treatments for highly symptomatic patients with 
obstructive HCM. Due to the lack of randomized controlled 
trials for direct comparison, physicians need to consider the 
advantages of each one when selecting patients for septal re-
duction therapy. Advantages of the ablation technique include 
the avoidance of a major surgical procedure, the lack of post-
operative pain and need for transfusion, the shorter hospital 
stay and the low incidence of atrial fibrillation.24 Advantages of 
the surgical technique are the immediate and permanent relief 
of LVOT gradient, the less need for a permanent pacemaker, 
the fact that coexisting mitral and coronary artery disease 
can be dealt with at the same time and the proven long-term 
efficacy. For the ablation procedure such long-term data are 
lacking56 and moreover the question of the possible arrhythmic 
risk due to scar formation remains unanswered. As noted by 
Maron et al, although there is an increasing enthusiasm for 
the ablation procedure among interventional cardiologists, we 
should remember that surgery is the most effective and long-
lasting treatment for alleviating symptoms of obstructive HCM 
and therefore it should be regarded as the primary treatment 
option for drug-refractory symptomatic patients.29
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